介孔二氧化硅纳米颗粒细胞毒性和体内外分布研究

Researches show that gene therapy has broad application prospects in the treatment of cancer pain. NR2B gene interference will be a new therapy to treat cancer pain. But clinical practices have been critical restricted because of the safety problem and inefficiency of existing vectors. Among a variety of inorganic nanoparticles, mesoporous silicate nanoparticles （MSNs）have several attractive advantages for application as a new gene vector, such as good biocompatibiligy, biodegradability, good chemical and thermal stability, tunable pore size, dual-functional surfaces, large surface areas and pore volumes and so on, it likely to be a new choice of gene vector. Using sol-gel method， we use 20 nm Fe304 nanoparicles as a core , MSNs package Fe304 nanoparicles and then amino-modified the Fe304/Si02 nanocomposite materials . The structure and morphology of these particles were characterized by transmission electron microscopy. MTT and flowcytometry test show that the cytotoxicity of MSNs were low among the concentration 5ug/mL and 125ug/mL and NR2B gene siRNA plasmid can transfected by this functional modificated MSNs. We use the cell electron microscopy and the targeted stimulation experiment in vivo show that our MSNs can transport into cells, can metablised in vivo by kidney and can transported to targeted organ. Therefor we carry out the biological safety trials of MSN, and lay the foundation for the ultimately efficient, safe mesoporous silica vector used for gene therapy of cancer pain.